A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

This study tests a new drug combination — AMO959 with a radioactive therapy called lutetium-177 PSMA (which targets prostate-specific membrane antigen) plus a hormone-blocking drug — in men with advanced prostate cancer that no longer responds to hormone therapy and shows PSMA on scans. **You may be eligible if...** - You are 18 or older with confirmed prostate adenocarcinoma - Your cancer has spread and no longer responds to hormone therapy (metastatic castration-resistant) - A PSMA scan shows your cancer is PSMA-positive - Your testosterone levels are very low (under 50 ng/dL) - You have progressed on one hormone-blocking therapy (ARPI) and did not progress on more than one - Your general health is good (ECOG 0-2) **You may NOT be eligible if...** - Your cancer is of a different cell type (e.g., neuroendocrine) - You have already received chemotherapy for metastatic castration-resistant prostate cancer (for Phase 2) - Your PSMA scan is negative Talk to your doctor to see if this trial is right for you.